BioXcel Therapeutics, Inc. (BTAIQ) vs Sunshine Biopharma, Inc. (SBFM)
- BioXcel Therapeutics, Inc. BTAIQ 0.03 0.00%
- Sunshine Biopharma, Inc. SBFM 0.22 −4.35%
BioXcel Therapeutics, Inc. and Sunshine Biopharma, Inc. are both Drug Manufacturers Specialty & Generic companies. BioXcel Therapeutics, Inc. is the larger, with a market value of $2.3M against $990.0K — 2.3× the size. Sunshine Biopharma, Inc. grew revenue faster over the last twelve months: −2.74% against −14.5%. Sunshine Biopharma, Inc. has the higher net margin (−16.5% vs −9,549.9%) and the lower return on invested capital (−26.7% vs 0.00%). Across the 16 metrics below, Sunshine Biopharma, Inc. leads on 11 and BioXcel Therapeutics, Inc. on 5.
Valuation
| Metric | BTAIQ | SBFM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 19.25 |
| P/S | 1.23 | 0.01 | 2.11 |
| P/B | n/m | 0.01 | 1.78 |
| Price to free cash flow | n/m | n/m | 16.14 |
| EV/EBITDA | n/m | 2.38 | 12.58 |
| EV/Sales | 228.32 | (0.33) | 2.73 |
| Earnings yield | (12,633.33%) | (4,613.64%) | (4.38%) |
| Free cash flow yield | (5,602.20%) | (1,843.25%) | 0.00% |
Profitability
| Metric | BTAIQ | SBFM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.10% | 30.30% | 53.94% |
| Operating margin | (6,054.72%) | (16.65%) | 0.00% |
| Net margin | (9,549.87%) | (16.50%) | 0.00% |
| Free cash flow margin | (6,860.38%) | (15.66%) | 0.00% |
| Return on equity | 63.52% | (21.93%) | (0.40%) |
| Return on assets | (259.62%) | (17.78%) | (3.32%) |
| Return on invested capital | 0.00% | (26.67%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack